

STRAUMANN® EMDOGAIN® AND EMDOGAIN® FL

Mastering periodontal regeneration,
oral wound healing and peri-implant
treatment.



A black and white photograph of a smiling woman with dark hair, wearing a dark top, holding a potted plant with long, pointed leaves. The image is the background for the advertisement.

YOU CAN'T BUY **RESPECT.** YOU EARN IT.

Straumann® Emdogain® has earned the respect of thousands of periodontists, oral surgeons, implantologists and dentists around the world over the last 25 years.

Straumann® Emdogain® is the only biological solution that promotes the true regeneration of periodontal tissues¹ and enhances oral wound healing.² After 25 years of clinical success, Straumann® Emdogain® is still unique in the field of regenerative dentistry. There is nothing quite like it. While alternative treatments only slow down the advancement of periodontitis, Straumann® Emdogain® can actually regenerate the tissues lost due to periodontal disease.¹



LONG-TERM STABILITY

Documented in over 1000 publications⁶ including 10-year follow-up studies.^{3,4}



MORE PATIENT COMFORT

Enhances wound healing and leads to less pain and less postoperative swelling.^{15,16}



BETTER ESTHETIC OUTCOME


Provides enhanced esthetic results: keratinized tissue and improved recession coverage.¹⁴

DID YOU KNOW?


- Every 3 minutes a patient benefits from a treatment with Straumann® Emdogain® somewhere in the world.
- Straumann® Emdogain® is still manufactured in Malmö, the Swedish city where it was discovered in 1987 by Prof. Lars Hammerström.

TREATMENT

Courtesy of Prof. Carlos Nemcovsky



Before treatment with Straumann® Emdogain®



20 years after treatment with Straumann® Emdogain®

YOU CAN'T BUY **EXPERIENCE.** YOU GAIN IT.

Experience comes in time. Over the last 25 years, respected leaders in the field of regenerative dentistry have counted on Straumann® Emdogain® to improve the clinical outcome in various treatment indications. Some of them shared their experiences on the following pages.



"I have been using Emdogain® since 1998. The appropriate use of EMD in intraosseous and furcation lesions may help our patients in restoring the missing periodontal support, thus ensuring long-term retention of their dentition."



Prof. Leonardo Trombelli
Professor of Periodontology,
University of Ferrara, Italy



Prof. Adrian Kasaj
Professor of Periodontology,
University of Mainz, Germany

See full interviews on our website.





Prof. Anton Sculean
Professor of Periodontology,
University of Bern, Switzerland



"Emdogain® is a gold standard, having the most solid evidence among biological materials. I recommend it to every clinician that starts to work on periodontal regeneration."

"Emdogain® is very flexible and I can use it in several types of defects, not only intrabony, but also suprabony and furcation defects. And now, the new flapless application gives us four times more chance to obtain a complete resolution from the non-surgical phase of the treatment."



Prof. Filippo Graziani
Professor of Periodontology,
University of Pisa, Italy



"I started to use Emdogain® during my postgraduate education, either solely or combined with bone grafts. Apart from its effectiveness, the main advantages of Emdogain® compared to other regenerative approaches are that the material is easy-to-use due to its gel formulation and that it is associated with less postoperative complications."

STRAUMANN® EMDOGAIN®

Mastering periodontal regeneration.



Straumann® Emdogain®'s unique mixture of natural proteins forms a matrix that can induce biological processes that usually take place during the development of the periodontium and may stimulate certain cells involved in the healing

action of soft and hard tissues.⁷ By modulating the wound healing process, Straumann® Emdogain® induces the regeneration of a functional attachment in periodontal procedures as evidenced by human histological data.^{8,9}



MORE EFFICIENT

Straumann® Emdogain® provides higher clinical attachment level (CAL) gains and probing pocket depth (PPD) reductions,^{*}^{10,11} greater reductions in the horizontal depth of buccal class II furcations in mandibular molars^{** 12} and leads to more root coverage (RC).^{*** 13,14}



PROVEN REGENERATION

Straumann® Emdogain® supports the formation of new periodontal tissue¹ and the formation of periodontal attachment⁸ in conjunction with coronally advanced flap (CAF), as indicated by histological studies.



LONG-TERM STABILITY


The use of Straumann® Emdogain® leads to documented 10-year stable results in terms of osseous defect fill³ and root coverage.⁴

* compared to open flap debridement alone

** compared to membranes

*** compared to coronally advanced flap without Straumann® Emdogain®

"Straumann® Emdogain® is the only biomaterial that I am still using every single day for 25 years."



Prof. Giovanni Zucchelli
Professor of Periodontology,
University of Bologna, Italy



STRAUMANN® EMDOGAIN® IN FACTS AND FIGURES

> 25 years
on the market

**> 600 clinical
& 1,000 scientific
publications****

Stable results
documented
over 10 years
in two indications

> 2.5 million
patients treated*

Extremely
well tolerated***

* Based on the number of syringes sold to date, globally

** According to PUBMED search for "Emdogain" or
"enamel matrix derivative"

*** Based on a global post-surgical complication rate of
less than 0.003 %

DID YOU KNOW?

→ A single batch of Straumann® Emdogain® takes approximately 50 days to manufacture and more than 30 steps are performed merely to ensure that the product meets all quality requirements.

STRAUMANN® EMDOGAIN®

Mastering periodontal regeneration.

Patients' main concerns in oral surgical treatment are esthetics, comfort and efficiency, and Straumann® Emdogain® satisfies all these demands. By accelerating healing,¹⁵ it ensures less swelling and less pain,¹⁶ thus minimizing discomfort. Straumann® Emdogain® initiates and supports the natural healing process. As a result, patients recover faster and can begin to enjoy the esthetic outcomes they expect.¹⁷

TREATMENT

Pictures courtesy of Prof. George Furtado Guimarães, Brazil



Without Straumann® Emdogain®




With Straumann® Emdogain®

Patients receiving Straumann® Emdogain® are more likely to accept a complex treatment plan as they enjoy more comfort and feel reassured by the lower risk of complications. There is clinical evidence of accelerated wound healing after implant placement with Straumann® Emdogain® in the same patient. The site treated with Straumann® Emdogain® shows advanced healing and less swelling and redness 10 days post-surgery. Faster healing over the same period minimizes the risk of complications.¹⁷



“Data exists for the use of Straumann® Emdogain® alone for the management of severely compromised situations where initially questionable teeth have been maintained in stable situations for over 20 years following the therapy with Emdogain.®”

Dr. Richard Miron
DDS, Florida, USA



Significantly more patients are free of pain and swelling after treatment with Straumann® Emdogain® when compared to treatment with membranes (guided tissue regeneration – GTR) one-week post-surgery.¹⁸

STRAUMANN® EMDOGAIN® FL

Cultivating flapless periodontal regeneration.



Following decades of clinical success in regenerative periodontal surgery, and thanks to the introduction of a new applicator, Straumann® Emdogain® FL can now be applied flapless* in periodontal pockets after scaling and root planing procedures.




MORE EFFICIENT

Straumann® Emdogain® FL stimulates periodontal regeneration,^{19,20} significantly reduces the bleeding on probing (BOP) and pocket probing depth (PPD)²¹ and solves more periodontal pockets as part of the periodontal debridement process.²²



MORE PATIENT COMFORT

Straumann® Emdogain® FL improves the quality of life of patients by reducing pain, swelling¹⁵ and systemic inflammation and by significantly reducing the need for follow-up treatments including surgery.²²



IMPROVED NON-SURGICAL OUTCOME

Straumann® Emdogain® FL supports the flapless treatments and leads to results that are similar to the surgical procedure.²³

TREATMENT

Case courtesy of Prof. Filippo Graziani



Before: Periodontal pocket with probing depth of 7 mm



Flapless application of Straumann® Emdogain® FL



3 months after: Solved pocket with probing depth of 3 mm

* as described in the instructions for use for Emdogain® FL



TIPS AND TRICKS FOR SUCCESSFUL FLAPLESS PROCEDURES WITH STRAUMANN® EMDOGAIN® FL:

- Perform thorough scaling and root planing (SRP) using micro-mini curettes, ultrasonic instrumentation with fine tips and additional visual support (good light, micro-mirrors, loupes or other magnification devices – microscope if available)
- Dry the root surface as much as possible before applying Straumann® PrefGel® and Straumann® Emdogain® FL
 - Apply air spray for a few seconds immediately before product application
 - Use suction, absorbent sponges and sterile gauzes
 - Apply floss in bleeding pockets and leave in place for approx. 1 minute²²

STRAUMANN® EMDOGAIN® AND STRAUMANN® EMDOGAIN® FL

Mastering peri-implant treatment.

Adding Straumann® Emdogain® or Straumann® Emdogain® FL to the remedial treatment of peri-implant disease improves the clinical outcome of the procedure.^{24,25}

Peri-implant mucositis:

Straumann® Emdogain® FL significantly reduces* the probing depth (PD) and bleeding on probing (BOP).^{25,26}

Peri-implantitis:

Straumann® Emdogain® is positively associated with bone gain and implant survival and results in better treatment success.^{24,27,28}

Easy handling:

Straumann® Emdogain® and Straumann® Emdogain® FL are easy to apply due to the gel formulation and specific cannulas suitable for surgical and flapless use.

DID YOU KNOW?

- You are more likely to be struck by lightning than to experience a complication with Straumann® Emdogain®**
- Amelogenin, the main ingredient of Straumann® Emdogain's protein mix, is assumed to be 610 million years old?³⁰



* compared to conventional non-surgical therapy without Straumann® Emdogain® FL.

** Risk of complication with Emdogain 1 in 3333 cases.⁵ Risk of being hit by lightning in US: 1 in 3000.²⁹

STRAUMANN® EMDOGAIN® AND EMDOGAIN® FL



REFERENCES

- 1 Il Bosshardt DD. Biological mediators and periodontal regeneration: a review of enamel matrix proteins at the cellular and molecular levels. *J Clin Periodontol.* 2008;35 (8 Suppl):87-105.doi:10.1111/j.1600-051X.2008.01264.x. 2 Miron RJ, Dard M, Weinreb M. Enamel matrix derivative, inflammation and soft tissue wound healing. *J Periodontol Res.* 2015 Oct;50(5):555-69. 3 Sculean A, Kiss A, Miliauskaitė A, Schwarz F, Arweiler NB, Hannig M. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. *J Clin Periodontol.* 2008 Sep;35(9):817-24. 4 McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: comparison of clinical parameters at 10 years. *J Periodontol.* 2012 Nov;83(11):1353-62. 5 Based on the number of syringes sold globally and number of reported complaints. Data on file. 6 According to PUBMED search for "Emdogain" or "enamel matrix derivative". 7 Miron RJ, Sculean A, Cochran DL, et al. Twenty years of enamel matrix derivative: the past, the present and the future. *J Clin Periodontol.* 2016;43(8):668-683. doi:10.1111/jcpe.12546. 8 McGuire MK, et al. A Prospective, Cased-Controlled Study Evaluating the use of Enamel Matrix Derivative on Human Buccal Recession Defects: A Human Histologic Examination. *J Periodontol.* 2016 Feb 1:1-34. 9 Sculean A, et al. Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative (Emdogain). *Int J Periodontics Restorative Dent.* 2000;20:374-381. 10 Heijl L, Heden G, Svärdröm G, Ostgren A. Enamel matrix derivative (EMDOGAIN) in the treatment of intrabony periodontal defects. *J Clin Periodontol.* 1997 Sep;24(9 Pt 2):705-14. 11 Tonetti MS, Lang NP, Cortellini P, Suvan JE, Adriaens P, Dubravec D, Fonzar A, Fourmousis I, Mayfield L, Rossi R, Silvestri M, Tiedemann C, Topoll H, Vangsted T, Walkkamm B. Enamel matrix proteins in the regenerative therapy of deep intrabony defects. *J Clin Periodontol.* 2002 Apr;29(4):317-25. 12 Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, Reich E, Sculean A, Gonzales JR, Bödeker RH, Meyle J. A randomized clinical trial comparing enamel matrix derivative and mem-brane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. *J Periodontol.* 2004 Aug;75(8):1150-60. 13 Tonetti MS, Jepsen S; Working Group 2 of the European Workshop on Periodontology. Clinical efficacy of periodontal plastic surgery procedures: consensus report of Group 2 of the 10th Europe-an Workshop on Periodontology. *J Clin Periodontol.* 2014 Apr;41 Suppl 15:S36-43. 14 Pilloni A, Paolantonio M, Camargo PM. Root coverage with a coronally positioned flap used in com-bination with enamel matrix derivative: 18-month clinical evaluation. *J Periodontol.* 2006 Dec;77(12):2031-9. 15 Wennström JL, Lindhe J. Some effects of enamel matrix proteins on wound healing in the dento-gingival region. *J Clin Periodontol.* 2002 Jan;29(1):9-14. 16 Ozcelik O, Haytac MC, Seydaoglu G. Immediate post-operative effects of different periodontal treatment modalities on oral health-related quality of life: a randomized clinical trial. *J Clin Periodontol.* 2007 Sep;34(9):788-96. 17 Guimarães GF, de Araújo VC, Nery JC, Peruzzo DC, Soares AB. Microvessel Density Evaluation of the Effect of Enamel Matrix Derivative on Soft Tissue After Implant Placement: A Preliminary Study. *Int J Periodontics Restorative Dent.* 2015 Sep-Oct;35(5):733-8. 18 Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, Reich E, Sculean A, Gonzales JR, Bödeker RH, Meyle J. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. *J Periodontol.* 2004 Aug;75(8):1150-60. 19 Shujaa Addin A, Akizuki T, Matsuura T, Hoshi S, Ikawa T, Maruyama K, Ono W, Fukuba S, Izumi Y. Histological healing after non-surgical periodontal treatment with enamel matrix derivatives in canine experimental periodontitis. *Odontology.* 2018 Jul;106(3):289-296. 20 Mellonig JT, Valderrama P, Gregory HJ, Cochran DL. Clinical and histologic evaluation of non-surgical periodontal therapy with enamel matrix derivative: a report of four cases. *J Periodontol.* 2009 Sep;80(9):1534-40. 21 Jentsch HFR, Rocuzzo, M, Kasaj A, Fimmers R, Jepsen, S. Flapless application of enamel matrix derivative (EMD) as an adjunct to scaling and root planning – a multicenter RCT. Oral presentation O059 at Europerio 2018. 22 Graziani F, Gennai S, Petrini M, Bettini L, Tonetti M. Enamel matrix derivative stabilizes blood clot and improves clinical healing in deep pockets after flapless periodontal therapy: A Randomized Clinical Trial. *J Clin Periodontol.* 2019 Feb;46(2):231-240. 23 Aimetti M, Ferrarotti F, Mariani GM, Romano F. A novel flapless approach versus minimally invasive surgery in periodontal regeneration with enamel matrix derivative proteins: a 24-month randomized controlled clinical trial. *Clin Oral Investig.* 2017 Jan;21(1):327-337. 24 Esberg A, Isehmed C, Holmlund A, Lundberg P. Peri-implant crevicular fluid proteome before and after adjunctive enamel matrix derivative treatment of peri-implantitis. *J Clin Periodontol.* 2019. 46(6): p. 669-677. 25 Faramarzi M, Goharfar Z, Pourabbas R, Kashefimehr A, Shirmohammadi A. Microbiological and clinical effects of enamel matrix derivative and sustained-release micro-spherical minocycline application as an adjunct to non-surgical therapy in peri-implant mucosal inflammation. *Journal of the Korean Association of Oral and Maxillofacial Surgeons.* 2015;41(4):181-9. 26 Kashefimehr A, Pourabbas R, Faramarzi M, Zarandi A, Moradi A, Tenenbaum HC, et al. Effects of enamel matrix derivative on non-surgical management of peri-implant mucositis: a double-blind randomized clinical trial. *Clinical oral investigations.* 2017;21(7):2379-88. 27 Isehmed C, Holmlund A, Renvert S, Svenson B, Johansson I, Lundberg P. Effectiveness of enamel matrix derivative on the clinical and microbiological outcomes following surgical regenerative treatment of peri-implantitis. A randomized controlled trial. *Journal of clinical periodontology.* 2016;43(10):863-73. 28 Isehmed C, Svenson B, Lundberg P, Holmlund A. Surgical treatment of peri-implantitis using enamel matrix derivative, an RCT: 3- and 5-year follow-up. *Journal of clinical periodontology.* 2018;45(6):744-53. 29 National Geographic 2005, accessed 1 September 2020, <<https://www.nationalgeographic.com/news/2005/6/flash-facts-about-lightning>> 30 Sidney Delgado, Didier Casane, Laure Bonnaud, Michel Laurin, Jean-Yves Sire, Marc Girondot, Molecular Evidence for Precambrian Origin of Amelogenin, the Major Protein of Vertebrate Enamel, *Molecular Biology and Evolution*, Volume 18, Issue 12, December 2001, Pages 2146–2153, <https://doi.org/10.1093/oxfordjournals.molbev.a003760>.

International Headquarters

Institut Straumann AG

Peter Merian-Weg 12

CH-4002 Basel, Switzerland

Phone +41 (0)61 965 11 11

Fax +41 (0)61 965 11 01

www.straumann.com